OpGen Supports New White House National Microbiome Initiative

GAITHERSBURG, Md., May 17, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a leading developer of precision medicine tools to combat infectious disease in global healthcare settings, supports the new White House National Microbiome Initiative (NMI) and its more than $121 million of strategic investments from various Federal agencies into interdisciplinary and multi-ecosystem microbiome research and tools development. The NMI was announced on May 13, 2016.

“The OpGen team applauds and thanks the White House for its leadership and recognition of the importance of microbiomes,” said Evan Jones, Chairman and CEO of OpGen. “With this new initiative and its strategic investments, our hope is that OpGen will be included in NMI’s efforts to gain a deeper understanding of the microbiome, and how best to enable protections and restorations of healthy microbiome function.”

About OpGen

OpGen, Inc. is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping clinicians improve patient outcomes by providing more rapid information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics. Its QuickFISH® products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Clinical laboratory services utilize the Acuitas® products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse™ bioinformatics platform designed to detect, type, track and trend antibiotic resistant organisms in real-time. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.

OpGen media contact:
Cammy Duong
MacDougall Biomedical Communications

OpGen investor contact:
Kim Sutton Golodetz

Source:OpGen, Inc.